Dr. Lars Wagner, MD
Claim this profileDuke University Medical Center
Expert in Cancer
Expert in Lymphoma
51 reported clinical trials
98 drugs studied
About Lars Wagner, MD
Education:
- Earned an MD (Doctor of Medicine) from Duke University School of Medicine.
Experience:
- Serves as Chief in the Division of Pediatric Hematology-Oncology at Duke University Medical Center, with a focus on solid tumors and combination therapies for sarcoma.
- Actively involved in clinical trials and research projects, particularly in pediatric hematology-oncology, sickle cell disease, bone marrow transplantation, and sarcoma.
- Completed a sub-internship at Duke University Medical Center as part of the MD degree requirements.
Area of expertise
1Cancer
Global LeaderStage I
Stage IV
Stage II
2Lymphoma
Global LeaderStage IV
Philadelphia chromosome positive
BCR-ABL1 fusion positive
Affiliated Hospitals
Clinical Trials Lars Wagner, MD is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
More about Lars Wagner, MD
Clinical Trial Related7 years of experience running clinical trials · Led 51 trials as a Principal Investigator · 23 Active Clinical TrialsTreatments Lars Wagner, MD has experience with
- Cyclophosphamide
- Etoposide
- Radiation Therapy
- Vincristine Sulfate
- Laboratory Biomarker Analysis
- Carboplatin
Breakdown of trials Lars Wagner, MD has run
Lymphoma
Relapse
Osteosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lars Wagner, MD specialize in?
Lars Wagner, MD focuses on Cancer and Lymphoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Lars Wagner, MD currently recruiting for clinical trials?
Yes, Lars Wagner, MD is currently recruiting for 19 clinical trials in Durham North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Lars Wagner, MD has studied deeply?
Yes, Lars Wagner, MD has studied treatments such as Cyclophosphamide, Etoposide, Radiation Therapy.
What is the best way to schedule an appointment with Lars Wagner, MD?
Apply for one of the trials that Lars Wagner, MD is conducting.
What is the office address of Lars Wagner, MD?
The office of Lars Wagner, MD is located at: Duke University Medical Center, Durham, North Carolina 27710 United States. This is the address for their practice at the Duke University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.